The federal court paused a bid by Louisiana to immediately end the FDA’s 2023 mail-order rules for mifepristone, keeping the drug available by mail for now while ordering a formal safety review. A Trump-appointed judge signaled that the agency should finish its promised evaluation and warned the case could swing dramatically depending on that outcome. That sets up a clash between state efforts to roll back expanded access and federal regulators who must explain why they relaxed rules after the pandemic.
U.S. District Court Judge David C. Joseph allowed the current distribution rules to remain in effect while the Food and Drug Administration completes a safety review of the 2023 REMS policy. Joseph, appointed by President Donald Trump, emphasized that the court prefers the agency’s fact-based review to what he described as lawsuits shaping policy. “It is the completion of FDA’s promised good faith, evidence-based, and expeditious review of the mifepristone REMS, not “government by lawsuit,” that this Court finds to be in the public interest,” Joseph wrote in his ruling.
The suit brought by the State of Louisiana targets the “certified pharmacies” allowance that enabled mifepristone to be mailed across state lines. Louisiana Attorney General Liz Murrill says the state has standing and will press the issue at the Fifth Circuit after the trial court’s temporary decision. “Judge Joseph concluded that Louisiana has standing to sue and is likely to succeed in showing that the 2023 REMS is unlawful,” Murrill said to Fox News Digital in a statement.
Murrill argues the REMS inflicts daily harm on the state and believes legal precedent demands vacatur of the 2023 policy while litigation proceeds. “He also concluded that Louisiana suffers irreparable harm every day that the 2023 REMS remains in effect,” she added. “Accordingly, under binding Fifth Circuit precedent, the only thing left to do is vacate the 2023 REMS pending the outcome of this litigation. We will ask the Fifth Circuit to do so.”
The opinion instructs the FDA to finish the promised review and report back in six months, warning the court’s approach will change if the agency stalls. Joseph made clear the agency’s findings will carry weight as a public health judgment, but he left the door open for judicial action if deadlines are missed. “Should the agency fail to complete its review and make any necessary revisions to the REMS within a reasonable timeframe, the Court’s analysis – and the weight accorded to these factors – will inevitably change,” Joseph wrote in his ruling.
The legal fight is part of a broader push by conservative states to reclaim authority over abortion-related policy after Dobbs allowed states greater control. Joseph noted evidence the 2023 REMS may have been adopted in a way that effectively reaches into states that have restricted abortion. “Thus, in that post-Dobbs regulatory environment, there is evidence that the 2023 REMS was approved without adequate consideration, at least in part, as part of an effort to circumvent anti-abortion states’ ability to regulate abortion,” Joseph wrote. “Likewise, there is evidence that the consequences of this action were predictable – out-of-state providers and related entities would expand access to mifepristone in ways designed to reach into jurisdictions like Louisiana.”
The review was requested in part by HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary, who asked their agencies to conduct a comprehensive safety review of the REMS. That request prompted the judge to push the agency to finish what it promised and justify the rules that broadened access. If revisions follow, the practical availability of mail-ordered mifepristone could change quickly.
Mifepristone’s regulatory history shows gradual loosening: initially approved in 2000 with strict in-person requirements and a seven-week gestational limit, the rules shifted in 2016 to allow prescriptions up to 10 weeks and fewer visits. During the pandemic, emergency measures permitted mail distribution and those changes were later formalized under the 2023 REMS. Today, medication abortion accounts for a large majority of abortions in the U.S., with pill methods representing roughly 60 percent of procedures.
Conservative groups and some state officials insist FDA oversight must be stronger and faster so states can protect patients and enforce local rules if needed. “This is one of the many reasons why the investigation into the FDA must be sped up so that states can begin to regulate abortions if the feds don’t,” 40 Days for Life President Shawn Carney told Fox News Digital. “This was one of the great promises by RFK that they initiated last year, because we now know how dangerous these abortion drugs are.”
Carney added a blunt warning about the current distribution model and its risks in his view. “The investigation into the FDA must be sped up because every abortion pill sent through the mail is a huge, unregulated danger that has been a disaster since Biden deregulated it,” Carney added. That rhetoric captures why a fast, transparent FDA review matters to both federal officials and states pressing for legal remedies.
